Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02733588 · ClinicalTrials.gov registry record · Phase 2
Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Hypoglycemia in Post-Bariatric Surgery Patients
A Phase 2 study of Hypoglycemia and Complications of Bariatric Procedures, sponsored by Xeris Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT02733588 is a Phase 2 study of Hypoglycemia and Complications of Bariatric Procedures that has completed, run by Xeris Pharmaceuticals. The registered enrollment target is 8 participants, below the 506-participant average among 40 other Hypoglycemia trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02733588, a Phase 2 study of Hypoglycemia and Complications of Bariatric Procedures, has completed, sponsored by Xeris Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to test an optimized control system for sensor-guided (physician administered) delivery of glucagon, and test Proof-of-Concept (POC) in a clinical setting in patients with severe hypoglycemia following bariatric surgery.
Conditions Studied
Interventions
- DRUG G-Pump™ (glucagon infusion)
Study Locations (1)
Massachusetts
- Joslin Diabetes Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2016-03 |
| Est. Completion | 2017-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02733588
The ClinicalTrials.gov registry entry for NCT02733588 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 506-participant average among 40 other Hypoglycemia trials with a reported enrollment target (98% lower). The listed sponsor is Xeris Pharmaceuticals, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hypoglycemia appearing as the primary indexed condition, and to 1 intervention - of which G-Pump™ (glucagon infusion) is the first listed.
NCT02733588 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02733588 about?
NCT02733588 is a clinical study titled "Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Hypoglycemia in Post-Bariatric Surgery Patients". The primary objective of this study is to test an optimized control system for sensor-guided (physician administered) delivery of glucagon, and test Proof-of-Concept (POC) in a clinical setting in patients with severe hypoglycemia following bariatric surgery.
What is the current status of trial NCT02733588?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2016-03. Estimated completion is 2017-06-01.
What conditions does trial NCT02733588 study?
This clinical trial studies the following conditions: Hypoglycemia, Complications of Bariatric Procedures.
What interventions are being tested in trial NCT02733588?
The interventions under investigation include: G-Pump™ (glucagon infusion) (DRUG).
Who is sponsoring clinical trial NCT02733588?
This trial is sponsored by Xeris Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02733588 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypoglycemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia
COMPLETED · Phase 2
-
G-Pen™ for Hypoglycemia Rescue in T1D Patients
COMPLETED · Phase 2
-
External Carotid Blood Flow in Individuals With Post-Bariatric Hypoglycemia
RECRUITING
-
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
RECRUITING · Phase 1
-
Diabetes Clinical Decision Support
RECRUITING · NA
-
Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.